PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21306579-5	2011	CSE-evoked VEGF release was mimicked by its component acrolein at concentrations (10-100 microM) found in CSE, and prevented by the antioxidant and alpha,beta-unsaturated aldehyde scavenger, N-acetylcysteine (NAC).	Acrolein	54-62	vascular endothelial growth factor A	Homo sapiens	11-15	
21306579-6	2011	Both CSE and acrolein (30 microM) induced VEGF mRNA expression in ASMC cultures, suggesting an effect at transcriptional level.	Acrolein	13-21	vascular endothelial growth factor A	Homo sapiens	42-46	
21309688-2	2011	Our purpose was to investigate the potential of acrolein to influence the release of transforming growth factor beta-2 (TGFbeta2) and vascular endothelial growth factor (VEGF), to assess the ability of N-benzylhydroxylamine (NBHA) to prevent the effect of acrolein on cytokine release and reduction of viable cells, and to explore the pathway by which acrolein might be causing the increase of VEGF.	Acrolein	48-56	vascular endothelial growth factor A	Homo sapiens	134-168	
21309688-2	2011	Our purpose was to investigate the potential of acrolein to influence the release of transforming growth factor beta-2 (TGFbeta2) and vascular endothelial growth factor (VEGF), to assess the ability of N-benzylhydroxylamine (NBHA) to prevent the effect of acrolein on cytokine release and reduction of viable cells, and to explore the pathway by which acrolein might be causing the increase of VEGF.	Acrolein	48-56	vascular endothelial growth factor A	Homo sapiens	170-174	
21309688-6	2011	RESULTS: Acrolein was shown to reduce the number of viable ARPE-19 cells and to upregulate the release of the proangiogenic cytokines TGFbeta2 and VEGF.	Acrolein	9-17	vascular endothelial growth factor A	Homo sapiens	147-151	
21309688-8	2011	Pretreatment of the cells with SIS3 partially blocked the action of acrolein on decreased viable cell number and VEGF upregulation, suggesting that part of the effects of acrolein are mediated by the increased levels of TGFbeta and its signaling.	Acrolein	68-76	vascular endothelial growth factor A	Homo sapiens	113-117	
21309688-9	2011	CONCLUSIONS: Our results suggest that the action of acrolein on the reduction of viability and VEGF increase by ARPE-19 cells is partially mediated by TGFbeta2.	Acrolein	52-60	vascular endothelial growth factor A	Homo sapiens	95-99	
22906079-8	2012	RESULTS: In ARPE-19 cells exposed to acrolein and hyperglycemia there was reduced cell viability and an increase in the cell media of VEGF, TGFbeta1, and TGFbeta2, which was reversed by NBHA.	Acrolein	37-45	vascular endothelial growth factor A	Homo sapiens	134-138	
22906079-10	2012	CONCLUSIONS: We conclude that the effect of acrolein on the reduction of viability and VEGF increase by ARPE-19 cells in hyperglycemic media is conducted through the TGFbeta signaling pathway.	Acrolein	44-52	vascular endothelial growth factor A	Homo sapiens	87-91